Skip to content

Released Aug 8, 2024, before the open

10-Q filed Aug 8, 2024, 39 days after period end · 0001785530-24-000028

Q2 2024 · 10-Q
Revenue—
Net Income-$17.25MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.43N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$18,960,000N/M
Operating Cash Flowderived-$14,177,000N/M
Free Cash Flowderived-$14,194,000N/M

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Net Income-$17.25M-$5.10M-$14.59M-$10.92M
EPS Diluted-$0.43-$0.14-$0.53-$3.82

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR